4-Fluoro-2-hydroxybenzoic acid | CAS:345-29-9

We serve 4-Fluoro-2-hydroxybenzoic acid CAS:345-29-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Fluoro-2-hydroxybenzoic acid

Chemical Name:4-Fluoro-2-hydroxybenzoic acid
CAS.NO:345-29-9
Synonyms:4-Fluoro-2-hydroxybenzoic acid
4-Fluorosalicylic acid
4-fluoro-2-hydroxy-benzoic acid
Molecular Formula:C7H5FO3
Molecular Weight:156.11100
 
Physical and Chemical Properties:
Density:1.492
Melting point:170ºC
Boiling point:300.5ºC
Flash point:135.6ºC
Index of Refraction:1.513
 
Specification:
Appearance:White powder
Assay:≥98.0%
Moisture:≤0.2%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 4-Fluoro-2-hydroxybenzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-fluoro-2-hydroxy-benzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Fluorosalicylic acid Use and application,4-Fluorosalicylic acid technical grade,usp/ep/jp grade.


Related News: We manufacture APIs and drug manufacturers make medicines from APIs.methyl 2-sulfanylacetate manufacturer The national airlines of Egypt, Qatar and Saudi Arabia have halted flights to and from China.Methyl 4-amino-5-(ethylsulfonyl)-2-methoxybenzoate supplier The national airlines of Egypt, Qatar and Saudi Arabia have halted flights to and from China.4-Dibenzothienylboronic acid vendor China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.